

Influenza

## A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection

**Trial Status**  
Completed

**Trial Runs In**  
15 Countries

**Trial Identifier**  
NCT01715909 2012-002633-11  
NV25719

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This open-label, randomized, adaptive, 2-arm, multicenter study will evaluate the pharmacokinetics and pharmacodynamics of oseltamivir (Tamiflu) in immunocompromised children, less than (<) 13 years of age, with confirmed influenza infection. Participants will be randomized to receive either the standard dose or triple dose of oseltamivir orally daily for a minimum of 5 days and up to 20 days. Infants <1 year of age will be randomized to the standard dose arm only.

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT01715909 2012-002633-11 NV25719**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
<= 12 Years

**Healthy Volunteers**  
No

---